

## AFN-1252 tosylate

## Chemical Properties



CAS No. : 1047981-31-6

Formula: C<sub>29</sub>H<sub>29</sub>N<sub>3</sub>O<sub>6</sub>S

Molecular Weight: 547.62

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	AFN-1252 tosylate is an enoyl-ACP Reductase inhibitor.
Targets(IC50)	Others,Antibacterial,Antibiotic

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8261 mL	9.1304 mL	18.2608 mL
5 mM	0.3652 mL	1.8261 mL	3.6522 mL
10 mM	0.1826 mL	0.913 mL	1.8261 mL
50 mM	0.0365 mL	0.1826 mL	0.3652 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Rao KN, Lakshminarasimhan A, Joseph S, Lekshmi SU, Lau MS, Takhi M, Sreenivas K, Nathan S, Yusof R, Abd Rahman N, Ramachandra M, Antony T, Subramanya H. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from *Burkholderia pseudomallei*--Crystal structure, mode of action, and biological activity. *Protein Sci.* 2015 May;24(5):832-40. doi: 10.1002/pro.2655. Epub 2015 Apr 2. PubMed PMID: 25644789; PubMed Central PMCID: PMC4420531.
- Yao J, Maxwell JB, Rock CO. Resistance to AFN-1252 arises from missense mutations in *Staphylococcus aureus* enoyl-acyl carrier protein reductase (FabI). *J Biol Chem.* 2013 Dec 20;288(51):36261-71. doi: 10.1074/jbc.M113.512905. Epub 2013 Nov 4. PubMed PMID: 24189061; PubMed Central PMCID: PMC3868742.
- Kaplan N, Garner C, Hafkin B. AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. *Eur J Pharm Sci.* 2013 Nov 20;50(3-4):440-6. doi: 10.1016/j.ejps.2013.08.019. Epub 2013 Aug 27. Erratum in: *Eur J Pharm Sci.* 2014 Feb 14;52:223. PubMed PMID: 23988847.
- Banevicius MA, Kaplan N, Hafkin B, Nicolau DP. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. *J Chemother.* 2013 Feb;25(1):26-31. doi: 10.1179/1973947812Y.0000000061. PubMed PMID: 23433441; PubMed Central PMCID: PMC3558988.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481